Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL
Neeraj Saini, David Marin, Celina Ledesma, Ruby Delgado, Gabriela Rondon, Uday R Popat, Qaiser Bashir, Chitra M Hosing, Yago Nieto, Amin M Alousi, Muzaffar H Qazilbash, Stefan Ciurea, Elizabeth Shpall, Issa Khouri, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Richard E Champlin, Partow Kebriaei, Neeraj Saini, David Marin, Celina Ledesma, Ruby Delgado, Gabriela Rondon, Uday R Popat, Qaiser Bashir, Chitra M Hosing, Yago Nieto, Amin M Alousi, Muzaffar H Qazilbash, Stefan Ciurea, Elizabeth Shpall, Issa Khouri, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Richard E Champlin, Partow Kebriaei
Abstract
Publisher's Note: There is a Blood Commentary on this article in this issue.
Conflict of interest statement
Conflict-of-interest disclosure: P.K. has received research support from Amgen and Ziopharm; has served on advisory boards of Pfizer, Kite, and Novartis; and has received consulting fees from Jazz. F.R. has received research funding from BMS, Amgen, Xencor, Abbvie, and Orsenix; has served on advisory boards of BMS, Amgen, Astellas, AstraZeneca, Celgene, Orsenix, and Agios; and has received honoraria from BMS, Celgene, Astellas, Abbvie, AstraZeneca, Novartis, Orsenix, and Agios. The remaining authors declare no competing financial interests.
Figures
References
- Abou Dalle I, Jabbour E, Short NJ, Ravandi F. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Curr Treat Options Oncol. 2019;20(1):4.
- Warraich Z, Tenneti P, Thai T, et al. . Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Ph+ ALL, A Systematic Review. Biol Blood Marrow Transplant. 2020;26(3):e55-e64.
- Giebel S, Czyz A, Ottmann O, et al. . Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2016;122(19):2941-2951.
- Litzow MR. Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: is it imperative in the tyrosine kinase inhibitor era? Best Pract Res Clin Haematol. 2018;31(4):357-360.
- Carpenter PA, Snyder DS, Flowers MED, et al. . Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood. 2007;109(7):2791-2793.
- Akahoshi Y, Nishiwaki S, Mizuta S, et al. ; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation . Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Sci. 2019;110(10):3255-3266.
- Chen H, Liu K-Y, Xu L-P, et al. . Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. J Hematol Oncol. 2012;5:29.
- Brissot E, Labopin M, Beckers MM, et al. . Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100(3):392-399.
- Zhang FH, Ling YW, Zhai X, et al. . The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology. 2013;18(3):151-157.
- Pfeifer H, Wassmann B, Bethge W, et al. ; GMALL Study Group . Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2013;27(6):1254-1262.
- Kebriaei P, Saliba R, Rondon G, et al. . Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012;18(4):584-592.
- Short NJ, Jabbour E, Sasaki K, et al. . Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128(4):504-507.
- Soverini S, Vitale A, Poerio A, et al. . Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica. 2011;96(4):552-557.
- Soverini S, De Benedittis C, Papayannidis C, et al. . Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014;120(7):1002-1009.
Source: PubMed